The Small-Molecule Inhibitor MRIA9 Reveals Novel Insights into the Cell Cycle Roles of SIK2 in Ovarian Cancer Cells

@article{Raab2021TheSI,
  title={The Small-Molecule Inhibitor MRIA9 Reveals Novel Insights into the Cell Cycle Roles of SIK2 in Ovarian Cancer Cells},
  author={Monika Raab and Marcel Rak and Roberta Tesch and Khayal Gasimli and Sven Becker and Stefan Knapp and Klaus Strebhardt and Mourad Sanhaji},
  journal={Cancers},
  year={2021},
  volume={13}
}
Simple Summary The current standard therapy of ovarian cancers comprises a reductive surgery followed by a combination of taxane-platinum-based primary chemotherapy. However, despite an initial positive response, patients in the advanced stage showed relapse within months or even weeks. Thus, there is a need to find combinatorial therapies that permit overcoming the paclitaxel-associated resistance in patients. Here, we found that MRIA9, a newly developed small-molecule inhibitor of the salt… 

Figures from this paper

The non-apoptotic function of Caspase-8 in negatively regulating the CDK9-mediated Ser2 phosphorylation of RNA polymerase II in cervical cancer

A novel mechanism where nuclear Caspase-8 directly interacts with and inhibits the activity of CDK9, thereby modulating RNAPII-mediated global transcription, including those of cell-migration- and cell-invasion-associated genes is identified.

Structure-based design of selective, orally available salt-inducible kinase inhibitors that stimulate bone formation in mice

A lead compound, SK-124, increases bone formation and bone mass when given to mice by once-daily oral treatment and support the further development of specific SIK2/SIK3 inhibitors as a class of bone anabolic osteoporosis therapies.

References

SHOWING 1-10 OF 40 REFERENCES

A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel

ARN-3236 is the first orally available inhibitor of SIK2 to be evaluated against ovarian cancer in preclinical models and shows promise in inhibiting ovarian cancer growth and enhancing paclitaxel chemosensitivity.

Identification of molecular targets for the targeted treatment of gastric cancer using dasatinib

The data suggest dasatinib for treatment of GC based on its unique property, inhibiting a small number of key kinases (SRC, FRK, DDR1 and SIK2), highly expressed in GC patients.

Structure-Based Design of Selective Salt-Inducible Kinase Inhibitors.

The pyrido[2,3-d]pyrimidin-7-one-based p21-activated kinase (PAK) inhibitor G-5555 is adapted for the targeting of SIK, by exploiting differences in the back-pocket region of these kinases, and MRIA9, a chemical probe with dual SIK/PAK activity and excellent selectivity over other kinases is shown.

Boosting the apoptotic response of high‐grade serous ovarian cancers with CCNE1 amplification to paclitaxel in vitro by targeting APC/C and the pro‐survival protein MCL‐1

This study provides not only elements to understand the causes of taxane resistance in CCNE1‐amplified ovarian cancers but also suggests a new combinatorial strategy that may improve paclitaxel‐based efficacy in this highly lethal gynecological disease.

Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells

It is shown that Plk1 silencing can be achieved in several organs, although adverse events are rare, and the utility of an RNA interference-based model to assess responses to an inducible knockdown of PlK1 in adult mice is evaluated.

The structural basis of PI3K cancer mutations: from mechanism to therapy.

The structural, biochemical, and biologic mechanisms through which p85α regulates the cancer cell life cycle are reviewed with an emphasis on the recently discovered genetic alterations in cancer.

Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pK a Polar Moiety.

Mouse xenograft PK/PD studies concluded that dose-dependent pathway modulation was achievable and paves the way for further in vivo investigations of PAK1 function in cancer and other diseases.

Salt-Inducible Kinase 2: An Oncogenic Signal Transmitter and Potential Target for Cancer Therapy

The results of in vivo and in vitro studies regarding the SIK2 mechanism in different signaling pathways, particularly their regulation of cancer cells are discussed to provide new ideas for targeting Sik2 as a novel therapeutic strategy in tumor therapy.

Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1.

  • L. VassilevC. Tovar Li Chen
  • Biology, Chemistry
    Proceedings of the National Academy of Sciences of the United States of America
  • 2006
A selective small-molecule inhibitor of CDK1 is identified that reversibly arrests human cells at the G(2)/M border of the cell cycle and allows for effective cell synchronization in early mitosis.